Adições à morfologia e à biologia da nidificação de uma espécie neotropical de Centridini, Melanocentris dorsata (Lepeletier) (Anthophila)

Adições à morfologia e à biologia da nidificação de uma espécie neotropicalde Centridini, Melanocentris dorsata (Lepeletier) (Anthophila

Um caso de predação de Ancylometes rufus (Walckenaer, 1837) (Araneae, Ctenidae) por Tityus strandi (Werner, 1939) (Scorpiones, Buthidae) no sul da Amazônia

Um caso de predação de Ancylometes rufus (Walckenaer, 1837) (Araneae, Ctenidae) por Tityus strandi (Werner, 1939) (Scorpiones, Buthidae) no sul da Amazônia</htm

Ocorrência de formas imaturas de Aedes (Stegmyia) aegypti (Diptera, Culicidae) em Bromeliaceae durante surto de dengue no litoral paranaense, Sul do Brasil

Ocorrência de formas imaturas de Aedes (Stegmyia) aegypti (Diptera, Culicidae) em Bromeliaceae durante surto de dengue no litoral paranaense, Sul do Brasi

Habitat structure in the composition of leaf-litter insects in mosaic environment

Habitat structure in the composition of leaf-litter insects in mosaic environment </htm

Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC.

Ensaio clínico PROTEC, Protocolo nº 109MS408Abstract BACKGROUND: Patient-reported outcomes (PRO) and clinical outcomes give a broad assessment of relapsing-remitting multiple sclerosis (RRMS) disease. OBJECTIVE: The aim is to evaluate the effectiveness of delayed-release dimethyl fumarate (DMF) on disease activity and PROs in patients with RRMS in the clinic. METHODS: PROTEC, a phase 4, open-label, 12-month observational study, assessed annualized relapse rate (ARR), proportion of patients relapsed, and changes in PROs. Newly diagnosed and early MS (≤3.5 EDSS and ≤1 relapse in the prior year) patient subgroups were evaluated. RESULTS: Unadjusted ARR at 12 months post-DMF versus 12 months before DMF initiation was 75% lower (0.161 vs. 0.643, p < 0.0001) overall (n = 1105) and 84%, 77%, and 71% lower in newly diagnosed, ≤3.5 EDSS, and ≤1 relapse subgroups, respectively. Overall, 88% of patients were relapse-free 12 months after DMF initiation (84%, newly diagnosed; 88%, ≤3.5 EDSS; 88%, ≤1 relapse). PRO measures for fatigue, treatment satisfaction, daily living, and work improved significantly over 12 months of DMF versus baseline. CONCLUSION: At 12 months after versus 12 months before DMF initiation, ARR was significantly lower, the majority of patients were relapse-free, and multiple PRO measures showed improvement (overall and for subgroups), suggesting that DMF is effective based on clinical outcomes and from a patient perspective.Clinical trial: A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes (PROTEC), NCT01930708,info:eu-repo/semantics/publishedVersio

Tityus paraguayensis (Scorpiones: Buthidae) em copas de Callisthene fasciculata (Vochysiaceae) no Pantanal de Mato Grosso (Brasil)

Tityus paraguayensis (Scorpiones: Buthidae) em copas de Callisthene fasciculata (Vochysiaceae) no Pantanal de Mato Grosso (Brasil)